In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume.

Patients with CALR mutations began Jakafi with more severe disease, including higher peripheral blast counts, lower hemoglobin levels and worse marrow fibrosis, and after a longer median time from ...